Efficacy and safety of mitazalimab in combination with mFOLFIRINOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): An interim analysis of the optimize-1 phase 1b/2 study

被引：0

作者：

Prenen, Hans

Borbath, Ivan

Paula Geboes, Karen

Alexandre Cassier, Philippe

Lambert, Aurelien

Mitry, Emmanuel

Macarulla, Teresa

Taieb, Julien

Blanc, Jean-Frederic

Feliu Batlle, Jaime

Rodriguez Garrote, Mercedes

Pazo Cid, Roberto A.

Valladares-Ayerbes, Manuel

Nordbladh, Karin

Enell Smith, Karin

Ellmark, Peter

Carlsson, Malin

Pico de Coana, Yago

Vijay Ambarkhane, Sumeet

Van Laethem, Jean-Luc

机构：

[1] Univ Antwerp, Ctr Oncol Res CORE, Integrated Personalized & Precis Oncol Network IP, Antwerp, Belgium

[2] Clin Univ St Luc, Woluwe St Lambert, Belgium

[3] Ghent Univ Hosp, Div Digest Oncol, Dept Gastroenterol, Ghent, Belgium

[4] Ctr Leon Berard, Lyon, France

[5] Inst Cancerol Lorraine, Vandoeuvre Les Nancy, France

[6] Inst Paoli Calmettes, Marseille, France

[7] Vall DHebron Univ Hosp, Vall DHebron Inst Oncol VHIO, Barcelona, Spain

[8] Georges Pompidou European Hosp, Paris, France

[9] CHU Bordeaux, Hop Haut Leveque, Serv Hepato Gastroenterol & Oncol Digest, Bordeaux, France

[10] Hosp Univ La Paz, Madrid, Spain

[11] Hosp Univ Ramon y Cajal, Madrid, Spain

[12] Hosp Univ Servet, Zaragoza, Spain

[13] Virgen Rocio Univ Hosp, Seville, Spain

[14] Alligator Biosci AB, Lund, Sweden

[15] Univ Libre Bruxelles, Hop Erasme, Brussels, Belgium

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4139

引用

页数：1

共 50 条

[31] Impact of UGT1A1*28 polymorphism on tolerability in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with NALIRIFOX in NAPOLI 3
Abdelrahim, Maen
Khan, Gazala
Hatoum, Hassan
Zervoudakis, Alice
Dayyani, Farshid
Zhang, Li
Li, Jia
Maxwell, Fiona
O'Reilly, Eileen M.
Wainberg, Zev A.
Peters, Mary Linton Bounetheau
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 717 - 717
[32] Abemaciclib in combination with therapies for patients with metastatic breast cancer: a phase 1b study
Tolaney, Sara M.
Jhaveri, Komal
Helsten, Teresa
Puhalla, Shannon L.
Conlin, Alison
Dees, E. Claire
Beeram, Muralidhar
Chapman, Sonya C.
Lithio, Andrew
Litchfield, Lacey M.
Goetz, Matthew P.
FRONTIERS IN ONCOLOGY, 2025, 15
[33] A phase 1b/2 study of omaveloxolone in combination with checkpoint inhibitors in patients with unresectable or metastatic melanoma
Patel, S. P.
Hodi, F. S.
Gabrilovich, D.
Chin, M.
Gibney, G.
Goldsberry, A.
Gonzalez, R.
Hurt, J.
Markowitz, J.
Whitman, E.
Meyer, C.
Salama, A.
ANNALS OF ONCOLOGY, 2017, 28
[34] Design of a phase 1b/2 study to evaluate the efficacy and safety of eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer
Berrak, E.
Atkan, G.
Song, J.
Almonte, A.
Karantza, V.
Yuan, R.
CANCER RESEARCH, 2016, 76
[35] Phase 1/1b Study of the Efficacy and Safety of the Combination of Panobinostat plus Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma
Shah, Jatin J.
Thomas, Sheeba K.
Weber, Donna M.
Wang, Michael
Alexanian, Raymond
Qazilbash, Muzaffar H.
Bashir, Qaiser
Parmar, Simrit
Shah, Nina
Popat, Uday R.
Orlowski, Robert Z.
BLOOD, 2012, 120 (21)
[36] Phase 1b/2 study of giloralimab in combination with modified FOLFIRINOX with or without budigalimab in patients with untreated metastatic pancreatic cancer.
Le, Dung T.
Cruz-Correa, Marcia
Bajor, David L.
Garcia-Carbonero, Rocio
Harris, Marion
Pazo-Cid, Roberto
Kindler, Hedy
Yee, Nelson
Kamath, Suneel
Patel, Maulik
Fang, Hua
Henner, William
Hardesty, Patrick
Blaney, Martha
McDevitt, Michael
Golan, Talia
CANCER RESEARCH, 2022, 82 (12)
[37] Safety and preliminary efficacy of ivaltinostat, an HDAC inhibitor, plus capecitabine in patients with pretreated metastatic pancreatic adenocarcinoma (mPDAC): Results of a phase Ib study.
Fountzilas, Christos
Ko, Andrew H.
Borazanci, Erkut Hasan
D'Olimpio, James Thomas
Hecht, Joel R.
Tang, Shou-Ching
Shields, Anthony F.
Salkeni, Mohamad Adham
Michelson, Glenn C.
Liganor, Lorna
Cho, Gene
Cho, Sangsook Ahn
Walker, Evan Justin
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL)
[38] Phase 1b/2 trial of cancer stemness inhibitor napabucasin (NAPA) plus nab-paclitaxel (nPTX) and gemcitabine (Gem) in metastatic pancreatic adenocarcinoma (mPDAC).
Bekaii-Saab, Tanios S.
Starodub, Alexander
El-Rayes, Bassel F.
Shahda, Safi
O'Neil, Bert H.
Noonan, Anne M.
Shaib, Walid Labib
Hanna, Wahid Tewfik
Mikhail, Sameh
Neki, Anterpreet S.
Chang, Yue
Dai, Xiaoshu
Li, Wei
Brooks, Emily
Oh, Cindy
Borodyansky, Laura
Li, Chiang
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[39] Safety and efficacy of the combination of sonidegib and ruxolitinib in myelofibrosis: a phase 1b/2 dose-finding study
Gupta, Vikas
Wolleschak, Denise
Hasselbalch, Hans
Vannucchi, Alessandro Maria
Koschmieder, Steffen
Cervantes, Francisco
Li, Yang
Dong, Tuochuan
Wroclawska, Monika
Bharathy, Savita
Harrison, Claire
BLOOD ADVANCES, 2020, 4 (13) : 3063 - 3071
[40] Early dose reduction/delay and the efficacy of liposomal irinotecan with fluorouracil and leucovorin in metastatic pancreatic ductal adenocarcinoma (mPDAC): A post hoc analysis of NAPOLI-1
Chen, Li-Tzong
Macarulla, Teresa
Blanc, Jean-Frederic
Mirakhur, Beloo
de Jong, Floris A.
Belanger, Bruce
Bekaii-Saab, Tanios
Siveke, Jens T.
PANCREATOLOGY, 2021, 21 (01) : 192 - 199

← 1 2 3 4 5 →